
Richard S P Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1626714/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. Modern Pathology, 2021, 34, 252-263.	5.5	78
2	Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer. Cancer Medicine, 2021, 10, 53-61.	2.8	39
3	Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. JAMA Network Open, 2022, 5, e225394.	5.9	37
4	Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors. AAPS Journal, 2020, 22, 132.	4.4	27
5	Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer. Oncologist, 2020, 25, 943-953.	3.7	19
6	Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. Modern Pathology, 2021, 34, 1425-1433.	5.5	19
7	Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. Oncologist, 2022, 27, 839-848.	3.7	18
8	Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors. Frontiers in Neurology, 2020, 11, 544680.	2.4	16
9	Clinicopathologic and Genomic Landscape of Breast Carcinoma Brain Metastases. Oncologist, 2021, 26, 835-844.	3.7	16
10	Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate Cancer. European Urology, 2022, 81, 37-47.	1.9	16
11	Clinicopathologic, genomic and protein expression characterization of 356 <scp> <i>ROS1 </i> </scp> fusion driven solid tumors cases. International Journal of Cancer, 2021, 148, 1778-1788.	5.1	14
12	Pan-cancer landscape of <i>CD274</i> (PD-L1) copy number changes in 244 584 patient samples and the correlation with PD-L1 protein expression. , 2021, 9, e002680.		13
13	Circulating Cell-Free DNA Yield and Circulating-Tumor DNA Quantity from Liquid Biopsies of 12 139 Cancer Patients. Clinical Chemistry, 2021, 67, 1554-1566.	3.2	13
14	Treatment of Pediatric Clioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. Oncologist, 2020, 25, e198-e202.	3.7	11
15	Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry. Pathology and Oncology Research, 2021, 27, 592997.	1.9	11
16	Clinical and pathological features associated with circulating tumor DNA content in realâ€world patients with metastatic prostate cancer. Prostate, 2022, 82, 867-875.	2.3	10
17	Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies. JCO Precision Oncology, 2022, , .	3.0	10
18	Clinically Advanced Pheochromocytomas and Paragangliomas: A Comprehensive Genomic Profiling Study. Cancers, 2021, 13, 3312.	3.7	9

RICHARD S P HUANG

#	Article	IF	CITATIONS
19	Correlating ROS1 Protein Expression With ROS1 Fusions, Amplifications, and Mutations. JTO Clinical and Research Reports, 2021, 2, 100100.	1.1	8
20	Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. Oncologist, 2021, 26, 375-382.	3.7	8
21	Pan-cancer landscape of <i>CD274</i> (PD-L1) rearrangements in 283,050 patient samples, its correlation with PD-L1 protein expression, and immunotherapy response. , 2021, 9, e003550.		8
22	Pan-cancer analysis of <i>CD274</i> (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression. , 2021, 9, e002558.		7
23	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. Cancer, 2021, 127, 4557-4564.	4.1	5
24	Association of <i>CD274</i> (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer. Oncologist, 2022, 27, 732-739.	3.7	5
25	Genomic landscape of nonâ€smallâ€cell lung cancer with methylthioadenosine phosphorylase (<scp>MTAP</scp>) deficiency. Cancer Medicine, 2023, 12, 1157-1166.	2.8	5
26	Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus chemotherapy benefit in first-line metastatic urothelial carcinoma: A real-world study Journal of Clinical Oncology, 2022, 40, 547-547.	1.6	4
27	Genomic evolution from hormonal therapies and suitability of prostate cancer diagnostic specimens for metastatic prostate cancer (mPC) genomic stratification Journal of Clinical Oncology, 2022, 40, 143-143.	1.6	2
28	Clustered 8-Oxo-Guanine Mutations and Oncogenic Gene Fusions in Microsatellite-Unstable Colorectal Cancer. JCO Precision Oncology, 2022, 6, e2100477.	3.0	2
29	Landscape of fibroblast growth factor receptor (<i>FGFR</i>) genomic alterations (GA) in urothelial bladder cancer (UBC) Journal of Clinical Oncology, 2022, 40, 4568-4568.	1.6	2
30	Genomic landscape of <i>MSH6</i> -mutated clinically advanced castrate-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2021, 39, 5062-5062.	1.6	1
31	Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study Journal of Clinical Oncology, 2021, 39, 3130-3130.	1.6	1
32	Genomic classification of clinically advanced pancreatic ductal adenocarcinoma (PDAC) based on methylthioadenosine phosphorylase (<i>MTAP</i>) genomic loss (<i>MTAP </i> loss) Journal of Clinical Oncology, 2022, 40, 604-604.	1.6	1
33	OUP accepted manuscript. Oncologist, 2022, , .	3.7	1
34	Molecular characteristics of advanced colorectal cancer and multi-hit <i>PIK3CA</i> mutations Journal of Clinical Oncology, 2022, 40, 3535-3535.	1.6	1
35	Plasma circulating tumor DNA (ctDNA) fraction and real-world overall survival (rwOS) in metastatic castration resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2021, 39, e17035-e17035.	1.6	0
36	Genomic landscape of non-small cell lung cancer (NSCLC) with methylthioadenosine phosphorylase (<i>MTAP</i>) deletion Journal of Clinical Oncology, 2021, 39, 9116-9116.	1.6	0

RICHARD S P HUANG

#	Article	IF	CITATIONS
37	Molecular, immunologic, and clinicodemographic landscape of MYC-amplified (MYCamp) advanced prostate cancer (PCa) Journal of Clinical Oncology, 2021, 39, 5041-5041.	1.6	Ο
38	Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype Journal of Clinical Oncology, 2021, 39, 8555-8555.	1.6	0
39	Pan-cancer analysis of <i>CD274</i> (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression Journal of Clinical Oncology, 2021, 39, 2605-2605.	1.6	Ο
40	Association of <i>RB1</i> mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC) Journal of Clinical Oncology, 2022, 40, 156-156.	1.6	0
41	Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study Journal of Clinical Oncology, 2022, 40, 162-162.	1.6	0
42	Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UBC) genomic alteration (GA) profile Journal of Clinical Oncology, 2022, 40, 563-563.	1.6	0
43	Genomic classification of clinically advanced major genito-urinary cancers (GUca) based on methylthioadenosine phosphorylase (<i>MTAP</i>) genomic loss Journal of Clinical Oncology, 2022, 40, 164-164.	1.6	Ο
44	Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with clear cell RCC (ccRCC): Impact of <i>FLCN</i> genomic alteration (GA) status Journal of Clinical Oncology, 2022, 40, 292-292.	1.6	0
45	Abstract PD4-09: Comprehensive assessment of the genomic landscape of breast cancer brain metastases reveals targetable alterations and genomic signatures relevant to immune-checkpoint and PARP inhibitors. Cancer Research, 2022, 82, PD4-09-PD4-09.	0.9	Ο
46	The mutational profile of ER-, PR+, HER2- metastatic breast cancer Journal of Clinical Oncology, 2022, 40, 1025-1025.	1.6	0
47	Comprehensive genomic profiling (CGP) of chromophobe renal cell carcinoma (chrRCC) compared with non-chromophobe RCC (nonchrRCC): Impact of <i>FLCN</i> genomic alteration (GA) status Journal of Clinical Oncology, 2022, 40, 4550-4550.	1.6	0
48	Targetable genomic mutations in young women with advanced breast cancer Journal of Clinical Oncology, 2022, 40, 1027-1027.	1.6	0
49	Distinct mutational landscapes characterize melanomas metastatic to different anatomical sites Journal of Clinical Oncology, 2022, 40, 9562-9562.	1.6	0
50	Pan-cancer landscape of <i>CD274</i> (PD-L1) and <i>PDCD1LG</i> 2 (PD-L2) structural variations Journal of Clinical Oncology, 2022, 40, 3133-3133.	1.6	0
51	Impact of PD-L1 expression on conventional urothelial bladder carcinoma (UCB) genomic alteration (GA) profile Journal of Clinical Oncology, 2022, 40, e16535-e16535.	1.6	Ο